Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media

Virology Journal

Volumn 9, Issue , 2012, Pages

  Lynch, Alisson ^a   Meyers, Ann E ^a   Williamson, Anna Lise ^b,c   Rybicki, Edward P ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

HIV vaccine; Human immunodeficiency virus; Osmolytes; Pr55gag; Thermostability; Virus like particles

Indexed keywords

SORBITOL; SUCROSE; TREHALOSE;

ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS; INSECT CELL; NONHUMAN; STORAGE; TEMPERATURE; TRANSMISSION ELECTRON MICROSCOPY; VIRUS LIKE AGENT;

ANIMALS; CELL LINE; COLD TEMPERATURE; CULTURE MEDIA; HIV-1; HUMANS; OSMOLAR CONCENTRATION; PRESERVATION, BIOLOGICAL; PROTEIN PRECURSORS; PROTEIN STABILITY; SF9 CELLS; TREHALOSE; VIRION;

ANIMALIA; HEXAPODA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84866271502     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-210     Document Type: Article

References (25)

1. UNAIDS, AIDS Epidemic Update 2009 http://www.unaids.og/en/dataanalysis/ epidemiology/2009aidsepidemicupdate.
2. Accelerating HIV, vaccine development. Koff WC, Nature 2010 464 161 162 10.1038/464161a 20220821
3. HIV Vaccines: Progress to Date. Munier CML, Andersen CR, Kelleher AD, Drugs 2011 71 387 414 21395355
4. Virus-like particles as HIV-1 vaccines. Doan LX, Li M, Chen C, Yao Q, Rev Med Virol 2003 15 75 88
5. Virus-like particle and DNA-based candidate AIDS vaccines. Yao Q, Bu Z, Vzorov A, Yang C, Compans RW, Vaccine 2003 21 638 643 10.1016/S0264-410X(02) 00572-8 12531332
6. gag virus-like particles: potent stimulators of innate and acquired immune responses. Deml L, Speth C, Dietrich MP, Wolf H, Wagner R, Mol Immunol 2005 42 259 277 10.1016/j.molimm.2004.06.028 15488613
7. Large-scale production and purification of VLP-based vaccines. Vicente T, Roldao A, Peixoto C, Carrondo M, Alves PM, J Invert Pathol 2011 107 42 48
8. Studies on processing, particle formation and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Wagner R, Fliessbach H, Wanner G, Motz G, Niedrig M, Deby G, von Brunn A, Wolf H, Arch Virol 1992 127 117 137 10.1007/BF01309579 1456888
9. Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. Jaffray A, Shephard E, van HJ, Williamson C, Williamson AL, Rybicki EP, J Gen Virol 2004 85 409 413 10.1099/vir.0.19396-0 14769898
10. gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. Chege GK, Shephard E, Meyers AE, van Harmelen JH, Williamson C, Lynch A, Gray CM, Rybicki EP, Williamson AL, J Gen Virol 2008 89 2214 2227 10.1099/vir.0.83501-0 18753231
11. A prime-boost immunization regimen using recombinant BCG and Pr55gag virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Chege GK, Thomas R, Shephard E, Meyers AE, Bourn W, Williamson C, Maclean J, Gray CM, Rybicki EP, Williamson AL, Vaccine 2009 27 4857 4866 10.1016/j.vaccine.2009.05.064 19520196
12. Immunisation with a mixture of HIV Env DNA and VLP vaccines augments induction of CD8 T cell responses. Ye L, Wen W, Dong K, Pan L, Bu Z, Compans RW, Zhang H, Yang C, J Biomed Biotechnol 2010 10 1 11
13. Thermostability of vaccines. Galazka A, Milstien A, Zaffran J, World Health Programme for Vaccines and Immunization 1998 1 64
14. Thermal stability of vaccines. Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR, J Pharm Sci 2003 92 218 231 12532371
15. Hochachka PN, Somero GN, Biochemical Adaptation 2002
16. Effects of naturally occurring osmolytes on protein stability and solubility: issues important in protein crystallization. Bolen DW, Methods 2004 34 312 322 10.1016/j.ymeth.2004.03.022 15325649
17. Physical stabilization of Norwalk virus-like particles. Kissman J, Ausar SF, Foubert TR, Brock J, Switzer MH, Detzi EJ, Vedivick TS, Middaugh R, J Pharm Sci 2008 97 4208 4218 10.1002/jps.21315 18300304
18. Downstream processing of triple layered rotavirus like particles. Peixoto C, Sousa MF, Silva AC, Carrondo MJ, Alves PM, J Biotechnol 2007 127 452 461 10.1016/j.jbiotec.2006.08.002 16959354
19. Rational design of an influenza subunit vaccine powder with sugar glass technology: Preventing conformational changes of haemagglutinin during freezing and freeze-drying. Amorij J-P, Meulenaar J, Hinrichs WLJ, Stegmann T, Huckriede A, Coenen F, Frijlink HW, Vaccine 2007 25 6447 6457 10.1016/j.vaccine.2007.06. 054 17673338
20. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. Burgers WA, van Harmelen JH, Shephard E, Adams C, Mgwebi T, Bourn W, Hanke T, Williamson AL, Williamson C, J Gen Virol 2006 87 399 410 10.1099/vir.0.81379-0 16432028
21. Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. van Harmelen JH, Shephard E, Thomas R, Hanke T, Williamson AL, Williamson C, Vaccine 2003 21 4380 4389 10.1016/S0264-410X(03) 00406-7 14505921
22. In vitro processing of human immunodeficiency virus type 1 Gag virus-like particles. Morikawa Y, Shibuya M, Goto T, Sano K, Virology 2000 272 366 374 10.1006/viro.2000.0370 10873780
23. Bozzola JJ, Russell LD, Electron Microscopy: Principles and Techniques for Biologists 1999
24. Virus-like particles: Passport to immune recognition. Grgacic EVL, Anderson DA, Methods 2006 40 60 65 10.1016/j.ymeth.2006.07.018 16997714
25. Quantitative characterization of virus-like particles by asymmetrical flow field flow fractionation, electrospray differential mobility analysis, and transmission electron microscopy. Pease LF, Lipin DI, Tsai DH, Zachariah MR, Lua LHL, Tarlov MJ, Middelberg APJ, Biotechnol Bioeng 2009 102 845 855 10.1002/bit.22085 18958863